RDHL - FDA Grant News could Drive this Stock to a Double or More

2023-11-27 07:49:39 ET

DENVER, Colo., Nov 27, 2023 ( www.247marketnews.com )- Redhill Biopharma Ltd (NASDAQ: RDHL) stated, this morning, that the U.S. Food and Drug Administration granted the Company five years’ market exclusivity for Talicia3 under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board. This grant is on top of three years’ exclusivity granted for the approval of Talicia under section 505(b)(2). Talicia is protected by its broad intellectual property suite to 2034.

Redhill Biopharma is trading at 0.59, up $0.275 (+87.00%), on 6.36M premarket shares.

Redhill Biopharma’s 52-week range is $0.257 to $16.00. If trading volume can strengthen, it may chew through its mid-October trading resistance and begin to challenge …

The post FDA Grant News could Drive this Stock to a Double or More appeared first on 24/7 Market News .

For further details see: